NPPA seeks clarification on Gilead's drug pricing plea

National Pharmaceutical Pricing Authority has sought clarifications
from the company. Gilead had sought exemption from price control for
its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a
major chunk of Rs 140-crore market for chronic Hepatitis B in India.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-seeks-clarification-on-gileads-drug-pricing-plea/articleshow/73788094.cms

Comments

Popular posts from this blog

The Scroll and the Revolution: The Dilemmas of Writing about the Jews of Cuba

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply

The Right Tool for the Job: Foreign Policy Effectiveness and Nuclear Proliferation